Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03615326 |
|---|---|
| Brief Title: | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) |
| First Submitted : | July 31, 2018 |
| First Submitted that Met QC Criteria : | July 31, 2018 |
| First Posted : | August 3, 2018 |
| Last Update Submitted that Met QC Criteria : | July 21, 2022 |
| Last Update Posted : | July 22, 2022 |